Single Agent Alimta in Poor Performance Status in Patients With Non-Small Cell Lung Cancer (NSCLC)

Trial Profile

Single Agent Alimta in Poor Performance Status in Patients With Non-Small Cell Lung Cancer (NSCLC)

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Feb 2017

At a glance

  • Drugs Pemetrexed (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 12 Mar 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Sep 2016, according to ClinicalTrials.gov record.
    • 12 Mar 2015 Status changed from completed to active, no longer recruiting, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top